更快溶栓与急性缺血性卒中患者认知结局改善相关:AcT试验亚组分析
本研究为AcT随机临床试验的预设二次观察性队列分析,纳入加拿大18个卒中中心的英语受试者,在90至180天用电话蒙特利尔认知评估(T-MoCA)评估认知。结果显示,更短的症状发作至溶栓时间(OTN)与更高的T-MoCA评分及更低的认知损害 odds 相关,而门至针时间无此关联;阿替普酶与替奈普酶亚组间无差异。
要点
- 更短OTN时间与90至180天T-MoCA评分更高相关,门至针时间无此关联。
- OTN每增加1分钟,T-MoCA损害 odds 增加(OR 1.005,95%CI 1.001-1.009)。
- OTN每减少15分钟,T-MoCA损害概率降低7.3%。
核心结论
- 更快的OTN时间,无论使用阿替普酶还是替奈普酶,均与更高的T-MoCA评分及90天时更低的认知损害可能性相关。
- 更快的溶栓治疗可能减轻卒中后认知负担。
研究设计与样本
- 本研究为AcT随机临床试验(阿替普酶对比替奈普酶)的预设二次观察性队列分析。
- 认知结局在90至180天前瞻性收集,使用电话蒙特利尔认知评估(T-MoCA,范围0-22,<17为损害)。
主要发现
- 平均年龄66±13岁,女性占38.8%,平均T-MoCA评分为16±4。
- 更短OTN时间(而非门至针时间)与更高的T-MoCA评分相关(线性回归β -0.009,95%CI -0.016至-0.002)。
- OTN每增加1分钟,T-MoCA损害的 odds 增加(logistic回归OR 1.005,95%CI 1.001-1.009)。
- 阿替普酶与替奈普酶亚组间在治疗时间与认知的关系上无差异。
- OTN每减少15分钟,T-MoCA损害(评分<17)的概率降低7.3%。
关键数值与推荐
- T-MoCA评分范围0-22分,<17分定义为认知损害。
- 线性回归显示OTN与T-MoCA评分关联的β值为-0.009(95%CI -0.016至-0.002)。
- logistic回归显示OTN每增加1分钟,T-MoCA损害的OR为1.005(95%CI 1.001-1.009)。
- OTN每减少15分钟,T-MoCA损害概率降低7.3%。
临床怎么用
- 对于接受阿替普酶或替奈普酶溶栓的急性缺血性卒中患者,缩短症状发作至溶栓时间可能有助于改善90天认知结局。
- 认知评估可采用T-MoCA在90至180天进行电话随访。
局限性
- 仅50%符合条件的受试者完成了T-MoCA,可能存在选择偏倚。
- 为观察性队列分析,不能确立因果关系。
- 仅纳入英语使用者,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cognitive impairment after stroke is linked with poorer functional outcomes. Faster thrombolytic improves recanalization, 3-month functional recovery, and in-hospital survival. We examined whether faster treatment times from door-to-needle and symptom onset-to-needle (OTN) impacted cognition. METHODS: This study is a prespecified secondary observational cohort analysis of the AcT randomized clinical trial (Alteplase Compared to Tenecteplase; URL: https://www.clinicaltrials.gov; Unique identifier: NCT03889249) data. Eligible participants were English-speaking individuals who independently completed the trial's primary outcome and were recruited from 18 stroke centers within Canada. Prospective cognitive outcomes were collected at 90 to 180 days using a Telephone Montreal Cognitive Assessment (T-MoCA range, 0-22; <17 impairment). The primary aim was to assess cognitive performance and its relationship with treatment times (door-to-needle and OTN) at 90 to 180 days. Linear and logistic regression analyses were used to evaluate the relationship, adjusting for treatment allocation, age, sex, baseline National Institutes of Health Stroke Scale, education, ethnicity, and occlusion location. RESULTS: Three hundred ninety-nine (50%) of 791 eligible subjects completed the T-MoCA. The mean age was 66±13 years, 38.8% were female, and the mean T-MoCA score was 16±4. Shorter OTN times (but not door-to-needle) were associated with higher T-MoCA scores on linear regression (β, -0.009 [95% CI, -0.016 to -0.002]) and with increased odds of T-MoCA impairment for every 1-minute increase on logistic regression (odds ratio, 1.005 [95% CI, 1.001-1.009]). There was no difference between the alteplase and tenecteplase subgroups in the relationship between treatment times and cognition. Each 15-minute reduction in OTN was associated with a 7.3% reduction in the probability of impairment (score <17) on the T-MoCA. CONCLUSIONS: Faster OTN time, with either alteplase or tenecteplase, was associated with higher T-MoCA scores and reduced the likelihood of impairment at 90 days. Faster thrombolytic treatment may reduce cognitive burden after stroke.
引用
- Sujanthan S, Rajkumar G, Dainty KN, et al. Faster Thrombolysis Is Associated With Improved Cognitive Outcomes in Patients With Acute Ischemic Stroke Treated With Alteplase and Tenecteplase: A Substudy of the AcT Trial. Stroke. 2025. PMID: 40677228. doi:10.1161/STROKEAHA.125.051670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。